Yaohui (Gloria) Xu, MD, PhD
Position title: Professor and Director of Micrographic Surgery and Dermatologic Oncology Fellowship
Medical School: Sun Yat-sen University of Medical Sciences, China, 1990-1995
Graduate School: Pharmacology and Toxicology, Indiana University School of Medicine, IN, 1996-2001
Dermatology, Board Certified
Postdoctoral research fellowship: Adult Oncology, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA, 2001-2003
Mohs and procedural dermatology, Univ of Wisconsin, Madison, WI, 2009-2010
Dermatology, University of Chicago Hospitals, 2004-2007
Transitional year, Grand Rapids Medical Education & Research Center for Health Professions/Michigan State University, 2003-2004
Translational research focused on the discovery and validation of novel biomarkers and therapeutic targets in skin cancers, particularly melanoma, high-risk squamous cell carcinoma and basal cell carcinoma.
Mohs micrographic surgery in treating non-melanoma and melanoma skin cancers
Dermatologic surgery and laser surgery
Skin cancer detection, treatment and prevention
General adult dermatology
Training for medical students, dermatology residents, fellows and general practitioners
Research Areas of Study
Prognostic markers and therapeutic targets in skin cancers (melanoma, squamous cell carcinoma and basal cell carcinoma).
Clinical studies to improve accuracy in squamous cell carcinoma staging and its association with prognosis.
Quality improvement studies in dermatologic care.
Achilles’ heel in Melanoma – CRD-BP as a Potential Prognostic Marker and Therapeutic Target
Dates: 07/01/2014 – present
Sponsor: Dermatology Foundation Clinical Career Development Award for Dermatologic Surgery
Explore the Role of RNA-binding Protein in Melanoma Resistance to Treatment
Dates: 11/01/2014 – 04/30/2016
Sponsor: UW Institute for Clinical and Translational Research (ICTR) and UW Skin Disease Research Center (SDRC)
Explore the Role of CRD-BP in Cutaneous Squamous Cell Carcinoma (SCC)
Dates: 07/01/2011 – 12/31/2015
Sponsor: UW Department of Dermatology pilot funding
A Retrospective Review on the Number of Skin Biopsies Needed Per Malignancy
Dates: 11/01/2014 – 12/31/2016
Sponsor: UWSMPH (Shapiro scholarship award) and UW Department of Dermatology
Histologic Evaluation of Cutaneous SCC Debulk Specimens Prior to Mohs Micrographic Surgery and Its Influence on SCC Staging
Dates: 2015 – 2016
Sponsor: American Society for Dermatologic Surgery (ASDS) Cutting Edge Research Grant
Nault A, Zhang C, Kim K, Saha S, Bennett DD, Xu YG. Biopsy Use in Skin Cancer Diagnosis: Comparing Dermatology Physicians and Advanced Practice Professionals. JAMA Dermatology. 2015 Aug;151(8):899-902. doi: 10.1001/jamadermatol.2015.0173.
Xu YG, Aylward J, Longley BJ, Hinshaw MA, Snow SN. Eccrine Porocarcinoma Treated by Mohs Micrographic Surgery: Over Six-Year Follow-Up of Twelve Cases and Literature Review. Dermatol Surg 2015; 41:685-692. doi: 10.1097/DSS.0000000000000382.
Kasprzak JM, Xu YG. Diagnosis and management of lentigo maligna: a review. Drugs in Context 2015; 4: 212281. DOI: 10.7573/dic.212281.
Wood GS, Xu YG, et al. Nonmelanoma Skin Cancers chapter in Abeloff’s Clinical Oncology, 5th edition. Edited by Niederhuber et al, 2014.
Snow SN, Xu YG. Sebaceous gland carcinoma chapter, Mohs Micrographic Surgery, edited by Keyvan Nouri, MD, Springer Publishing Company, 2012.
Xu YG, Hinshaw M, Longley BJ, Ilyas H, Snow S. Cutaneous Adenoid Cystic Carcinoma with Perineural Invasion Treated by Mohs Micrographic Surgery – A Case Report with Literature Review – J Oncol 2010:469049. Epub 2010 Apr 7.
Xu YG, Ilyas H, Snow S. Cancers of the skin. Conn’s Current Therapy 2010 edition, Section 13: 805-809.
Sharma V, Xu Y, Petronic-Rosic V, Gerami P. Clinicopathologic challenge. Regional lymphomatoid papulosis, type A. Int J Dermatol. 2007; 46:905-909.
Xu Y, Petronic-Rosic V, Stein SL. Subepidermal calcified nodule in a 7-month-old boy. Skinmed 2007; 6:44-45.
Xu Y, LaCouture M, Petronic-Rosic V, Soltani K, Shea CR. Ossified soft tissue leiomyoma in a patient with sickle cell anemia. J Cutan Pathol 2005; 32: 696-699.
Xu Y, Stange-Thomann N, Weber G, Bo R, Dodge S, David RG, Foley K, Beheshti J, Harris NL, Birren B, Lander ES, Meyerson M. Pathogen discovery from human tissue by sequence-based computational subtraction. Genomics 2003; 81: 329-335.
Xu Y, Carr LG. Binding of Sp1/Sp3 to the proximal promoter of the human mu opioid receptor gene (hMOR) is enhanced by DAMGO. Gene 2001; 274: 119-128.
Xu Y, Carr LG. Transcriptional regulation of the human mu opioid receptor (hMOR) gene: evidence of positive and negative cis-acting elements in the proximal promoter and presence of a distal promoter. DNA Cell Biol 2001; 20: 391-402.
Xu Y, Carr LG. Functional characterization of the promoter region of the human mu opioid receptor gene: identification of activating and inhibitory regions. Cell Mol Biol 2001; 47: OL29-OL38.
American Academy of Dermatology, 2004 – present
Society for Investigative Dermatology, 2006 – present
Wisconsin Dermatological Society, 2007 – present
American Society for Dermatologic Surgery, 2010 – present
Association of Professors of Dermatology, 2011 – present
American College of Mohs Surgery, 2012 – present
American Medical Association, 2014 – present
Committees and Service Activities
National Comprehensive Cancer Network (NCCN) Non-Melanoma Skin Cancer Guideline Panel member, 2016 – present
Micrographic Surgery and Dermatologic Oncology Fellowship, Associate Program Director, 2015- present
Skin Diseases Research Center at the UWSMPH, Co-director of Cell Culture Center, 2014 – present
Department of Dermatology Educational Committee and Resident Interview Committee, 2007- present
Leadership role in establishing UW Melanoma Tumor Board, 2014 – present
Faculty advisor, medical student Dermatology Interest Group (DIG), 2012 – present
Diagnostic Quality Control and Teaching Library Committee for American College of Mohs Surgery, Member, 2013 – present
Wisconsin Public Radio Features